Clene Inc
CLNN
Get informed when a big investor buys or sells
+ FollowMarket Cap$52.9M
Close$
$-1.81
143.3% downside
Current Fair Value
143.3% downsideOvervalued by 143.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $52.90 Million |
|---|---|
| Enterprise Value | $65.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.65 |
| Beta | 0.97 |
| Outstanding Shares | 12,382,702 |
Return
| Return on Equity | 159.49% |
|---|---|
| Return on Assets | -171.51% |
| Return on Invested Capital | -118.16% |
Valuation & Multiples
| P/E Ratio | -1.17 |
|---|---|
| PEG | -1.44 |
| Price to Sales | - |
| Price to Book Ratio | -1.4 |
| Enterprise Value to Revenue | 332.87 |
| Enterprise Value to EBIT | -3.05 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | -0.9 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$61,000
Average shareholder expectationNext Earnings Call
Expected Date
August 17, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$63,250
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 18.84%▼ 0.81% |
|---|---|
| Total Invested | $10.81M▼ 4.91% |
| Investors Holding | 29▲ 1.00% |
ESG Score
No data
About Clene Inc
2,021 employeesClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally a...